Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleRadiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
- Where
- Shijiazhuang
- Age
- 18 years and over
- People
- 60
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT07179900 - No phaseTaking peopleTITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Fudan University
See details and how to joinNCT07268131 - No phaseNot yet taking people in ChinaAI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Where
- Wuhan
- Age
- 18 years and over
- People
- 2,000
- Run by
- Tongji Hospital
See details and how to joinNCT07732504 - Phase 2Taking peopleQL1706(Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 38
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07733115 - Phase 1/2Taking peopleMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Where
- Beijing, Fuzhou, Lishui, Nanjing, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 160
- Run by
- Lepu Biopharma Co., Ltd.
See details and how to joinNCT07479485 - Phase 2Not yet taking people in ChinaPrecision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 240
- Run by
- Zhejiang University
See details and how to joinNCT07729917 - No phaseNot yet taking people in ChinaThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Where
- Guangzhou, Harbin, Kunming, Nanning, Qingdao, Shanghai
- Age
- 18 years and over
- People
- 400
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07724951 - Phase 2Not yet taking people in ChinaA Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 28
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07729033 - No phaseNot yet taking people in ChinaAI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years and over
- People
- 1,800
- Run by
- Tongji Hospital
See details and how to joinNCT07729618 - Phase 3Taking peopleA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 538
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07582315 - Phase 3Taking peopleA Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
- Where
- Beijing, Hefei
- Age
- 18 years to 75 years
- People
- 398
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07606599 - Phase 2Taking peopleStudy on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
- Where
- Tianjin
- Age
- 18 years and over
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07726446 - Phase 2Taking peopleA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- Where
- Fuzhou, Shanghai
- Age
- 18 years and over
- People
- 40
- Run by
- TaiRx, Inc.
See details and how to joinNCT07521852 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Beijing, Shanghai
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peopleCombined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
- Where
- Wuhan
- Age
- 18 years and over
- People
- 36
- Run by
- Tongji Hospital
See details and how to joinNCT06192797 - Phase 2/3Taking peopleCamrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
- Where
- Harbin, Shanghai
- Age
- 18 years to 75 years
- People
- 398
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06796803 - Phase 2Taking peopleDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT05640791 - Phase 2Taking peoplePhase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 70
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07704177 - Phase 1/2Taking peopleHepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 20
- Run by
- West China Hospital
See details and how to joinNCT07636798 - No phaseTaking peopleClinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 20
- Run by
- Fudan University
See details and how to joinNCT07459309 - Phase 2Not yet taking people in ChinaA Study of Combination Therapy in Patients With Resectable Liver Cancer
- Where
- Zhanjiang
- Age
- 18 years and over
- People
- 68
- Run by
- Affiliated Hospital of Guangdong Medical University
See details and how to joinNCT07684040 - Phase 2Not yet taking people in ChinaA Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 120
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07682272 - Phase 2Taking peopleA Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 222
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07679399 - Phase 1Taking peopleA Study of DEG6498 in Participants With Solid Tumors
- Where
- Beijing, Guangzhou
- Age
- 18 years and over
- People
- 100
- Run by
- Degron Therapeutics Co.
See details and how to joinNCT07244835 - Phase 2Taking peoplePhase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 70
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07670273